From - Mon Nov  5 09:42:14 2007
Received: from mail.mdanderson.org (mail.mdanderson.org [143.111.251.38])
        by wotan.mdacc.tmc.edu (8.13.6/) with ESMTP id lA5EYD4N027520
        for <kabagg@wotan.mdacc.tmc.edu>; Mon, 5 Nov 2007 08:34:13 -0600 (CST)
Received: from ([171.66.121.166])
	by mdairnmail1.mdacc.tmc.edu with ESMTP  id KP-BRAYX.116395445;
	Mon, 05 Nov 2007 08:33:52 -0600
Received: from madcap.stanford.edu (madcap.stanford.edu [171.66.121.176])
	by highwire.stanford.edu (Postfix) with ESMTP id D40CE8E24;
	Mon,  5 Nov 2007 06:33:51 -0800 (PST)
Message-ID: <23872732.1194273231797.JavaMail.netsite@highwire.stanford.edu>
From: gunne@asco.org
To: kabagg@mdanderson.org, crboucha@mdanderson.org
Subject: New Correspondence - JCO/2007/151985
Mime-Version: 1.0
Content-Type: text/plain; charset=us-ascii
Content-Transfer-Encoding: 7bit
Date: Mon,  5 Nov 2007 06:33:51 -0800 (PST)
X-esp: ESP<-8>=
	SHA:<0> 
	UHA:<6> 
	ISC:<0> 
	BAYES:<-4> 
	SenderID:<0> 
	DKIM:<0> 
	TS:<-10> 
	SIG:<dgWhqDN1Akyht0fz-qMMXK96uq1EK6Xa9DzMhBRpUYGISMe3O0TJthpFWF_7
	Sz5iuYfdCu1sOJQ8gW_BfbepLP1AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
	AAAAAAAAAAAAAAAAAAAknKPG5tQRZVvmXLr_lCRkL1LEm5ciPT3GQLnGNX6H
	bLa0hVFc4WkRmknA9pXipsWlkAYC85RsvMDXuzeqdcIwdqFAA>
	TRU_stock_spam: <0>
	TRU_profanity_spam: <0>
	TRU_money_spam: <0>
	TRU_legal_spam: <0>
	TRU_lotto_spam: <0>
	TRU_phish_spam: <0>
	TRU_html_image_spam: <0>
	TRU_medical_spam: <0>
	TRU_embedded_image_spam: <0>
	TRU_adult_spam: <0>
	TRU_marketing_spam: <0>
	TRU_misc_spam: <0>
	TRU_scam_spam: <0>
	URL Real-Time Signatures: <0>
	TRU_watch_spam: <0>
X-Mozilla-Status: 8001
X-Mozilla-Status2: 00000000
X-UIDL: ?1h"!##Q!!_X$"!oa""!

TITLE:Pharmacogenomic Strategies May Not Provide a Rational Approach to the
Treatment of Cisplatin-Resistant Patients with Advanced Lung Cancer

Dear Dr. Baggerly:

We have received your correspondence, and it has been assigned the number
JCO/2007/151985. Daniel Haller, MD, Editor-in-Chief, has assumed responsibility
for the editorial review.  Upon completion of the review, you will receive
notification of the Editors' decision.  

Thank you for submitting this letter to the Journal of Clinical Oncology.  

Sincerely,

Emilie Gunn
JCO Editorial Office


Privacy Notice:
The contents of this electronic message, including any prior messages,
files, or attachments transmitted with it, are CONFIDENTIAL and are intended
solely for the use of the individual(s) to whom the message is addressed. This
message may contain legally protected or privileged information. Do not read,
copy, disclose or forward this message without authorization from the originator
of this message.  If you have received this message in error, please notify the
sender immediately and delete all copies from your system.

NENC